# Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis

> **NCT01719159** · PHASE2 · COMPLETED · sponsor: **Anders Svenningsson** · enrollment: 23 (actual)

## Conditions studied

- Progressive Multiple Sclerosis

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01719159
- **Lead sponsor:** Anders Svenningsson
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2016-11-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01719159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01719159, "Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01719159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*